KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Operating Leases (2019 - 2025)

Nektar Therapeutics (NKTR) has 7 years of Operating Leases data on record, last reported at $69.7 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 19.62% year-over-year to $69.7 million; the TTM value through Sep 2025 reached $69.7 million, down 19.62%, while the annual FY2024 figure was $82.7 million, 16.06% down from the prior year.
  • Operating Leases reached $69.7 million in Q3 2025 per NKTR's latest filing, down from $74.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $134.6 million in Q1 2021 and bottomed at $69.7 million in Q3 2025.
  • Average Operating Leases over 5 years is $104.5 million, with a median of $105.8 million recorded in 2023.
  • Peak YoY movement for Operating Leases: decreased 5.44% in 2021, then fell 19.62% in 2025.
  • A 5-year view of Operating Leases shows it stood at $125.7 million in 2021, then decreased by 10.27% to $112.8 million in 2022, then fell by 12.68% to $98.5 million in 2023, then dropped by 16.06% to $82.7 million in 2024, then decreased by 15.68% to $69.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $69.7 million in Q3 2025, $74.1 million in Q2 2025, and $78.5 million in Q1 2025.